Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ronald Scott

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Journal of Medical Genetics|March 22, 2015
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P Germain, Joel Charrow, Robert J Desnick, et al.
Plos One|May 9, 2015
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trialFrits A Wijburg, Bernard Bénichou, Daniel G Bichet, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Molecular Genetics and Metabolism|April 17, 2019
Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trialUma Ramaswami, Daniel G Bichet, Lorne A Clarke, et al.
Molecular Genetics and Metabolism|August 14, 2012
Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in QuébecJean Larochelle, Fernando Alvarez, Jean-François Bussières, et al.
Seminars in Hematology|October 7, 2004
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patientsNeal J Weinreb, Mario C Aggio, Hans C Andersson, et al.
Human Mutation|July 12, 2016
Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular CarcinomaPatrick R Blackburn, Raymond D Hickey, Rebecca A Nace, et al.
American Journal of Human Genetics|September 24, 2013
Actionable, pathogenic incidental findings in 1,000 participants' exomesMichael O Dorschner, Laura M Amendola, Emily H Turner, et al.
Journal of Pediatric Gastroenterology and Nutrition|October 30, 2012
Research progress reported at the 50th Anniversary of the Discovery of Congenital Sucrase-Isomaltase Deficiency WorkshopMark Gilger, Bruce Hamaker, Buford L Nichols, et al.
The New England Journal of Medicine|August 11, 2016
Treatment of Fabry's Disease with the Pharmacologic Chaperone MigalastatDominique P Germain, Derralynn A Hughes, Kathleen Nicholls, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Journal of Medical Genetics|March 22, 2015
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P Germain, Joel Charrow, Robert J Desnick, et al.
Plos One|May 9, 2015
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trialFrits A Wijburg, Bernard Bénichou, Daniel G Bichet, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Molecular Genetics and Metabolism|April 17, 2019
Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trialUma Ramaswami, Daniel G Bichet, Lorne A Clarke, et al.
Molecular Genetics and Metabolism|August 14, 2012
Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in QuébecJean Larochelle, Fernando Alvarez, Jean-François Bussières, et al.
Seminars in Hematology|October 7, 2004
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patientsNeal J Weinreb, Mario C Aggio, Hans C Andersson, et al.
Human Mutation|July 12, 2016
Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular CarcinomaPatrick R Blackburn, Raymond D Hickey, Rebecca A Nace, et al.
American Journal of Human Genetics|September 24, 2013
Actionable, pathogenic incidental findings in 1,000 participants' exomesMichael O Dorschner, Laura M Amendola, Emily H Turner, et al.
Journal of Pediatric Gastroenterology and Nutrition|October 30, 2012
Research progress reported at the 50th Anniversary of the Discovery of Congenital Sucrase-Isomaltase Deficiency WorkshopMark Gilger, Bruce Hamaker, Buford L Nichols, et al.
The New England Journal of Medicine|August 11, 2016
Treatment of Fabry's Disease with the Pharmacologic Chaperone MigalastatDominique P Germain, Derralynn A Hughes, Kathleen Nicholls, et al.
Pageof 9